Other

FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List

FDA Announces Major Steps to Implement Real-Time Clinical Trials

Warning Letter — The Wilatta Group Inc.: Office of Inspections and Investigations

FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order

FDA Achieves Year 1 Goals in Reducing Animal Testing in Drug Development

Revival Animal Health, LLC Voluntarily Recalls Canine Milk Replacers Due to Elevated Levels of Vitamin D

FDA Takes Step Forward on Testosterone Therapy for Men

FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results

Blueroot Health Expands Voluntary Allergy Alert on Undeclared Egg, Hazelnut, and Soy in Vital Nutrients Aller-C Dietary Supplements

Blaine Labs, Inc Issues Voluntary Nationwide Recall of Wound Care Gel Products Due to Microbial Contamination

Nalpac Issues Voluntary Nationwide Recall of DTF Sexual Chocolate Due to the Presence of the Pharmaceutical Ingredient’s Sildenafil and Tadalafil

Aphreseller (Buy-herbal.com) Issues Voluntary Nationwide Recall of Kian Pee Wan Capsules Due the Presence of Undeclared Dexamethasone and Cyproheptadine

FDA Schedules Public Meeting on the Commissioner’s National Priority Voucher Pilot Program

FDA Launches New Adverse Event Look-Up Tool